Cara Therapeutics Inc (NASDAQ:CARA) Director Sells $64,575.00 in Stock

Share on StockTwits

Cara Therapeutics Inc (NASDAQ:CARA) Director Jeffrey L. Ives sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $25.83, for a total value of $64,575.00. Following the completion of the sale, the director now directly owns 8,500 shares of the company’s stock, valued at $219,555. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ:CARA traded up $0.10 during mid-day trading on Wednesday, hitting $17.03. 2,483,305 shares of the stock were exchanged, compared to its average volume of 725,814. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -8.27 and a beta of 2.30. The firm’s 50-day simple moving average is $21.45 and its 200 day simple moving average is $21.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.21 and a current ratio of 4.21. Cara Therapeutics Inc has a fifty-two week low of $12.19 and a fifty-two week high of $27.55.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.15). The firm had revenue of $5.79 million for the quarter, compared to analyst estimates of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. On average, analysts predict that Cara Therapeutics Inc will post -2.55 EPS for the current fiscal year.

A number of research firms have recently issued reports on CARA. ValuEngine raised Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Cara Therapeutics in a research report on Tuesday. Zacks Investment Research cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald lifted their price target on Cara Therapeutics from $29.00 to $33.00 in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.54.

Large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC acquired a new stake in Cara Therapeutics during the 2nd quarter worth approximately $88,000. Russell Investments Group Ltd. acquired a new stake in Cara Therapeutics during the 3rd quarter worth approximately $110,000. Sfmg LLC acquired a new stake in Cara Therapeutics during the 2nd quarter worth approximately $200,000. Creative Planning acquired a new stake in Cara Therapeutics during the 2nd quarter worth approximately $207,000. Finally, Penserra Capital Management LLC acquired a new stake in Cara Therapeutics during the 3rd quarter worth approximately $180,000. 76.08% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Guidelines for Successful Channel Trading

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sean P. Downes Acquires 1,000 Shares of Universal Insurance Holdings, Inc.  Stock
Sean P. Downes Acquires 1,000 Shares of Universal Insurance Holdings, Inc. Stock
Cara Therapeutics Inc  Director Sells $64,575.00 in Stock
Cara Therapeutics Inc Director Sells $64,575.00 in Stock
Insider Selling: Five Prime Therapeutics Inc  Director Sells 32,090 Shares of Stock
Insider Selling: Five Prime Therapeutics Inc Director Sells 32,090 Shares of Stock
John P. Stupp, Jr. Sells 277 Shares of Atrion Co.  Stock
John P. Stupp, Jr. Sells 277 Shares of Atrion Co. Stock
CARREFOUR SA/S  Lifted to Hold at Zacks Investment Research
CARREFOUR SA/S Lifted to Hold at Zacks Investment Research
ABB Ltd.  Receives CHF 20.73 Consensus PT from Brokerages
ABB Ltd. Receives CHF 20.73 Consensus PT from Brokerages


© 2006-2019 Ticker Report